Clinical trials: Aggressive Behaviour
Lymphoma
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00032019
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 81 sites in United States, Puerto Rico
- Volunteers
- 78 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Bacterial Pneumonia
Clinical Trials to Reduce the Risk of Antimicrobial Resistance
The primary objective of this study is to demonstrate a low rate of emergence of antibiotic resistance in P. aeruginosa and Acinetobacter spp during the treatment of hospitalized patients with pneumonia requiring mechanical…
- Trial name
- NCT01570192
- Testing
- IV meropenem, I.V. Meropenem, Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h
- Where
- 11 sites in United States, France and 2 more
- Volunteers
- 43 people
- Sponsor
- University of Florida
Larynx Disease
Effect of Acid Suppression With Esomeprazole on Vocal Cord Granulomas
The purpose of this research study is to measure the effects of the drug, esomeprazole 40 mg (Nexium) or placebo (inactive drug) on vocal cord granulomas.
- Trial name
- NCT00567658
- Testing
- Esomeprazole
- Where
- United States
- Sponsor
- Vanderbilt University
Prostate Cancer
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if…
- Trial name
- STEEL (NCT03809000)
- Testing
- Radiation Therapy, Enzalutamide, Bicalutamide
- Where
- 108 sites in United States, Canada
- Volunteers
- 188 people
- Sponsor
- RTOG Foundation, Inc.
Aggression
Efficacy of Brief Mindfulness Based Self- Compassion Intervention for Management of Anger Among Adolescents
This study investigates the effectiveness of a short self-compassion mental intervention in reducing aggression among adolescents. Although they display potential, current solutions are arduous and time-consuming.
- Trial name
- NCT06544044
- Testing
- Brief Mindfulness' Self compassion
- Where
- Pakistan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Fatima Noor
Hyperuricemia
Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma
The primary objective was to evaluate the efficacy of rasburicase in terms of prevention and treatment of hyperuricemia related to Tumor Lysis Syndrome (TLS) in 2 populations of adult patients, previously treated or not with…
- Trial name
- GRAAL2 (NCT00664144)
- Testing
- Rasburicase (SR29142)
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 33 people
- Sponsor
- Sanofi
Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
This phase II trial is studying how well ixabepilone works in treating patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma
- Trial name
- NCT00058019
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial
The purpose of this study is to examine adherence to cardio-oncology consultation.
- Trial name
- CARMA (NCT05403736)
- Testing
- Cardiac Aggressive Risk MitigAtion Plan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Lymphoma, High-grade
Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas
The main purpose of the PETAL trial is to determine whether patients with aggressive non-Hodgkin's lymphomas with a persistently positive PET scan after two cycles of chemotherapy benefit from a change of the treatment protocol.
- Trial name
- PETAL (NCT00554164)
- Testing
- (R-)CHOP protocol, B-ALL protocol
- Where
- Germany
- Volunteers
- 1,073 people
- Sponsor
- University Hospital, Essen
Healthy
Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress
This research study is designed to find out if increasing the dietary intake of polyunsaturated fats improves concentration, motor skills and cardiovascular responses under stress.
- Trial name
- NCT00014027
- Testing
- Docosahexaenoic acid (DHA), Eicosapentaenoic acid
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Peripheral T-cell Lymphomas
Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
The primary objectives of this study are to: 1. establish the safety and dose limiting toxicities of combining alemtuzumab with CHOP chemotherapy for patients with newly diagnosed aggressive T-cell lymphomas; and 2.
- Trial name
- ACCAPELA (NCT00453427)
- Testing
- Alemtuzumab (Campath-1H)
- Where
- 5 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (also known as BLU-285), administered…
- Conditions
- Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease, Mast Cell Leukemia, Relapsed or Refractory Myeloid Malignancies
- Trial name
- NCT02561988
- Testing
- Avapritinib
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 86 people
- Sponsor
- Blueprint Medicines Corporation
Post-ERCP Pancreatitis, Pancreatitis
Short-Stay Aggressive Hydration to Prevent Post-ERCP Pancreatitis
Post-ERCP pancreatitis (PEP) is the most common serious adverse event after endoscopic retrograde cholangiopancreatography (ERCP), occurring in roughly 7-15% of patients.
- Trial name
- PuSH (NCT07776561)
- Testing
- Short-Stay Aggressive Hydration, Standard Peri-procedural Hydration, Rectal Indomethacin
- Where
- Australia
- Volunteers
- 1,300 people
- Sponsor
- Westmead Hospital
Prostate Cancer
Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer
A prostate cancer diagnosis starts a list of events that often leads to fast-moving treatment, thought by many to result in vast over-treatment of this disease.
- Trial name
- MRSI+RRP (NCT01780701)
- Testing
- Magnetic Resonance Spectroscopy Imaging with rectal probe
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- OHSU Knight Cancer Institute
Attention Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder
Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders
Attention Deficit/Hyperactivity Disorder (ADHD) is one the most prevalent mental disorders among children and adolescents, with a prevalence of 5% in western culture.
- Conditions
- Attention Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder
- Trial name
- NCT02063945
- Testing
- Methylphenidate, Risperidone
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Sheba Medical Center
Conduct Disorder, Antisocial Behavior
The Effectiveness of Forensic Outpatient Systemic Therapy: a Multiple Case Experimental Design
The purpose of this study is to investigate the effectiveness and mediators of Forensic Outpatient Systemic Therapy (FAST).
- Conditions
- Conduct Disorder, Antisocial Behavior, Aggression, Behavioral Disorder
- Trial name
- FAST (NCT06032520)
- Testing
- FAST
- Where
- 2 sites in Netherlands
- Volunteers
- 21 people
- Sponsor
- Utrecht University
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
This phase II trial is studying how well PXD101 works in treating patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
- Trial name
- NCT00303953
- Testing
- belinostat
- Where
- 123 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma
A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
This is an open-label, multicenter, Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of EMB-07 combination therapy in adult patients with aggressive B-cell…
- Conditions
- Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma, EMB07, phaseI/II
- Trial name
- NCT07432022
- Testing
- EMB07, Rituximab/Gemcitabine/Oxaliplatin
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Kidney Cancer
Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00908739
- Testing
- gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Sponsor
- Case Comprehensive Cancer Center
Non Hodgkin's Lymphoma, NHL
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
The goal of this study is to evaluate a new approach to immunotherapy in NHL by combining two antibodies, veltuzumab and epratuzumab.
- Conditions
- Non Hodgkin's Lymphoma, NHL, Aggressive NHL, Diffuse Large B-cell Lymphoma
- Trial name
- NCT01101581
- Testing
- Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab tetraxetan, veltuzumab
- Where
- 7 sites in United States
- Sponsor
- Gilead Sciences